June 9, 2015
BALTIMORE — Myocardial scintigraphy, which is molecular imaging of the heart, can be used to predict major adverse cardiac events (MACE) in patients with transthyretin-type amyloidosis, according to results from a new study.
When the procedure is performed routinely with the bone radiotracer technetium-99m hydroxymethylene diphosphonate (99mTc-HMDP) as a part of the diagnostic work for transthyretin-type cardiac amyloidosis, it could "potentially save lives" by prompting a complete cardiac work-up in at-risk patients, said lead investigator Axel Van Der Gucht, MD, from Henri Mondor Hospital in Créteil, France.
... Dr Van Der Gucht and his colleagues evaluated 55 patients diagnosed with transthyretin-type amyloidosis who underwent both whole-body and cardiac 99mTc-HMDP scintigraphy.
He presented the results here at the Society of Nuclear Medicine and Molecular Imaging 2015 Annual Meeting.